← Back to Search

Proteasome Inhibitor

Carfilzomib + Sotorasib for Lung Cancer

Irvine, CA

Phase 1

Recruiting

Led By Jyoti Malhotra, MD (Co-PI)

Research Sponsored by City of Hope Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Creatinine clearance of ≤ 1.5 x ULN or GFR ≥ 60 mL/min/1.73 m^2

Failed prior KRAS inhibitor

Must not have

Active infection requiring antibiotics

Known history of HIV with detectable viral load

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from the start of treatment until disease progression/recurrence, assessed up to 30 days after completion of study treatment

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing the safety and effectiveness of using a combination of two drugs, carfilzomib and sotorasib, to treat patients with a specific type of lung cancer called KRAS

See full description

Who is the study for?

This trial is for adults with advanced or metastatic non-small cell lung cancer that has a specific mutation called KRAS G12C. Participants should have measurable disease and may have had prior treatments, but there are certain criteria they must meet to join.Check my eligibility

What is being tested?

The trial is testing the combination of two drugs, Carfilzomib and Sotorasib, to see if they're safe together, what the best dose might be, and how well they work against this type of lung cancer. It includes tests like CT scans, MRIs, biopsies, and heart checks.See study design

What are the potential side effects?

Possible side effects from Carfilzomib could include fatigue, nausea, shortness of breath among others. Sotorasib may cause diarrhea or liver issues. The study will monitor patients closely for any adverse reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My kidney function is within the normal range.

show original

Select...

I have tried a KRAS inhibitor treatment without success.

show original

Select...

My heart function is classified as good or better.

show original

Select...

I am able to get out of my bed or chair and move around.

show original

Select...

I am 18 years old or older.

show original

Select...

My lung cancer is advanced or has spread, and tests show a KRASG12C mutation.

show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am currently taking antibiotics for an infection.

show original

Select...

I have HIV with a detectable viral load.

show original

Select...

I couldn't tolerate the drug sotorasib at 240 mg daily.

show original

Select...

I have chronic hepatitis B with a detectable virus level.

show original

Select...

I do not have any uncontrolled serious illnesses.

show original

Select...

I have chronic hepatitis C that has not been treated.

show original

Select...

I do not have severe heart failure, recent heart attack, or uncontrolled heart rhythm problems.

show original

Select...

I do not have another cancer that affects this treatment's safety or results.

show original

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 30 days after completion of study treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 30 days after completion of study treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 30 days after completion of study treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Incidence of dose limiting toxicities

Incidence of grade 3 and 4 treatment-related toxicities

Secondary study objectives

Duration of response

Objective response rate

Overall survival

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (carfilzomib, sotorasib)Experimental Treatment7 Interventions

Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16 of each cycle and sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO at screening and undergo CT or MRI and collection of blood samples at screening and on study. Patients may undergo optional biopsies on study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Echocardiography

2013

Completed Phase 4

~11580

Magnetic Resonance Imaging

2020

Completed Phase 3

~1180